$HLN

Haleon plc (HLN) has secured better shelf space at Walmart (WMT), Target (TGT), and other retailers, leading to a US market share increase from 11.4% to 12% by August, per NielsenIQ data. The company achieved this through lower prices, promotions, and exclusivity, but profitability impact is unclear. Competitors like Procter & Gamble and Colgate-Palmolive saw flat or declining shares. Haleon's strategy may face challenges from promotional dependence and competitor responses.

Haleon (NYSE:HLN) targets U.S. growth by addressing GLP-1 drug side effects, seeing a 24% sales increase in CVS stores. North America showed Q2 2026 organic revenue growth of 3.1%. The strategy focuses on Advil and Digestive Health products, with potential expansion to Walmart and Target. Haleon's 2025 North American revenue was £3.87 billion, with a 0.4% decline. The company aims to leverage GLP-1 trends to boost U.S. performance.

Haleon, maker of Tums and Advil, reports increased sales of products addressing GLP-1 drug side effects. The company, spun off from GSK in 2022, sees potential in the growing GLP-1 market, with 10% of Americans using these weight-loss drugs. Haleon's shares have fallen 9.3% in 2026, and it aims for 3%-5% full-year revenue growth. The company is partnering with retailers like CVS to boost sales.

Haleon, maker of Advil and TUMS, reported a 24% sales lift in U.S. stores by targeting consumers on GLP-1 weight-loss drugs. The company partners with CVS Pharmacy, Walmart, and Target to place products in GLP-1-specific sections and regular aisles. About 11% of Americans use GLP-1 drugs, per Gallup. CVS expanded its product assortment to help manage side effects.

Walmart (WMT) and Target (TGT) are gaining better supplier deals, like Haleon's lower prices and promotions, for prime shelf space. Haleon's US market share rose from 11.4% to 12% due to this strategy. The retailers aim to attract cost-conscious shoppers, but face challenges from weak consumer spending and promotional dependency.

Haleon is investing £175m in a new oral health manufacturing facility in Madhya Pradesh, India, aiming to expand production capacity and reach more consumers, including rural populations with limited access to dental care. The company seeks to leverage local talent and infrastructure while addressing specific healthcare challenges and distribution hurdles in the region.

Deutsche Bank analysts expect European consumer staples stocks to underperform due to structural pressures and slower consumer spending growth. They cite competition from retailers like Amazon and Costco, and reduced sell-in rates in the US. The bank adjusted ratings and price targets for several companies, including Beiersdorf, Danone, Haleon, Henkel, and The Magnum Ice Cream Company.

Sensodyne, owned by Haleon, lost an appeal to advertise its toothpaste as the 'No.1 dentist-recommended' brand without specifying it's for sensitive teeth. The Advertising Regulatory Board (ARB) ruled the claim misleading, requiring equal prominence for the sensitivity disclaimer. Haleon argued the ARB lacked jurisdiction, but the committee upheld the ruling, citing a Supreme Court precedent.

Haleon, the maker of Sensodyne, secured better shelf space at Walmart and Target by offering lower prices, promotions, and exclusivity. According to the company, this has driven its US market share up to 12% in August from 11.4% in February. Rival P&G's share slipped to 10.8% in July, while Colgate-Palmolive's remained flat at under 5%.

Sugatha Karthikeyan, a former Hindustan Unilever (HUL) executive, will join Haleon as Region Head - West in 2026. She spent 11 years at HUL, most recently as Consumer Cluster Head for Delhi NCR and Rajasthan, managing teams and operations with annual sales of around ₹6,000 crore. Karthikeyan also held roles in sales, marketing, and brand management at HUL, including leading the Bru coffee brand. She previously worked at Airtel and holds an MBA from IIM Indore.